Search

Search Constraints

You searched for: Author/Creator Bahary, Nathan

Search Results

1. 260 T cell infiltrating repertoire diversity is associated with enhanced survival following neoadjuvant therapy in patients with resectable pancreatic cancer. (9th November 2020)

2. 260 T cell infiltrating repertoire diversity is associated with enhanced survival following neoadjuvant therapy in patients with resectable pancreatic cancer. (9th November 2020)

3. 90Y-clivatuzumab tetraxetan with or without low-dose gemcitabine: A phase Ib study in patients with metastatic pancreatic cancer after two or more prior therapies. Issue 14 (September 2015)

4. 90Y-clivatuzumab tetraxetan with or without low-dose gemcitabine: A phase Ib study in patients with metastatic pancreatic cancer after two or more prior therapies. Issue 14 (September 2015)

5. A phase 2 trial of regorafenib as a single agent in patients with chemotherapy‐refractory, advanced, and metastatic biliary tract adenocarcinoma. Issue 6 (18th December 2018)

6. Automated Quantitation of CD8-positive T Cells Predicts Prognosis in Colonic Adenocarcinoma With Mucinous, Signet Ring Cell, or Medullary Differentiation Independent of Mismatch Repair Protein Status. (July 2020)

7. Comparative Effectiveness of Sphincter-Sparing Surgery Versus Abdominoperineal Resection in Rectal Cancer. Issue 1 (January 2015)

8. Comparative Effectiveness of Sphincter-Sparing Surgery Versus Abdominoperineal Resection in Rectal Cancer: Patient-Reported Outcomes in National Surgical Adjuvant Breast and Bowel Project Randomized Trial R-04. Issue 1 (January 2015)

9. Encouraging long‐term survival following autophagy inhibition using neoadjuvant hydroxychloroquine and gemcitabine for high‐risk patients with resectable pancreatic carcinoma. (24th September 2021)